UK Medtech Market Access In Practice: Aim High But Stay Grounded
Manufacturers must ensure there are commercial outlets for the products they are developing, given the speed of change in medtech markets. That was the key message for companies and innovators at the UK Med-Tech Expo Conference 2017.
You may also be interested in...
Artificial intelligence won’t transform pharma R&D, at least not anytime soon. But it is already impacting health care delivery and clinical trials.
Confusing and ineffective channels of innovation adoption and a lack of funding hamper the UK's reputation as one of the world's health care capitals and a driver of care excellence – in spite of its global brands, NICE, MHRA and the NHS itself. But changes that should transform market access are in place and are worthy of close attention in the next two to three years.
Changes are afoot for the four UK Diagnostic Evidence Co-operatives that help generate clinical and cost-effectiveness data for innovative IVDs. Companies worry it could mean diagnostic industry needs get lost among broad medtech targets. Also, a roundup of the British In Vitro Diagnostics Association's key priorities, including the EU IVD Regulation, procurement issues, antimicrobial resistance, and of course, Brexit, highlighted at the group's 2016 annual meeting.